Somewhat Positive Media Coverage Somewhat Unlikely to Affect Tyme Technologies (TYME) Stock Price
News stories about Tyme Technologies (NASDAQ:TYME) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tyme Technologies earned a daily sentiment score of 0.06 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.6566095034378 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Pre-Open Movers 03/14: (RKDA) (RFIL) (TYME) Higher; (EARS) (SILC) (SIG) Lower (more…) (streetinsider.com)
- BRIEF-FDA Acceptance Of IND For Tyme To Begin Phase II Trial In Pancreatic Cancer (reuters.com)
- FDA Acceptance of IND for Tyme to Begin Phase II Trial in Pancreatic Cancer (finance.yahoo.com)
- Tyme Technologies Inc (TYME) Given $8.83 Average Price Target by Brokerages (americanbankingnews.com)
- Tyme Technologies Inc (TYME) Short Interest Update (americanbankingnews.com)
A number of brokerages recently issued reports on TYME. Canaccord Genuity began coverage on Tyme Technologies in a research report on Wednesday, January 3rd. They issued a “buy” rating on the stock. Zacks Investment Research downgraded Tyme Technologies from a “hold” rating to a “sell” rating in a research report on Thursday, February 15th. BidaskClub downgraded Tyme Technologies from a “sell” rating to a “strong sell” rating in a research report on Saturday, February 3rd. Evercore ISI began coverage on Tyme Technologies in a research report on Friday, November 17th. They issued an “outperform” rating and a $7.00 price objective on the stock. Finally, HC Wainwright began coverage on Tyme Technologies in a research report on Friday, December 15th. They set a “buy” rating and a $8.00 price target on the stock. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $8.25.
In other Tyme Technologies news, CEO Steve Hoffman sold 17,986 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $3.82, for a total transaction of $68,706.52. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Tyme Technologies Company Profile
Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.